(NASDAQ: CTMX) Cytomx Therapeutics's forecast annual revenue growth rate of -14.08% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.49%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.69%.
Cytomx Therapeutics's revenue in 2024 is $119,178,000.On average, 5 Wall Street analysts forecast CTMX's revenue for 2024 to be $8,190,416,553, with the lowest CTMX revenue forecast at $6,152,513,376, and the highest CTMX revenue forecast at $11,879,119,482. On average, 5 Wall Street analysts forecast CTMX's revenue for 2025 to be $6,675,430,262, with the lowest CTMX revenue forecast at $3,895,968,450, and the highest CTMX revenue forecast at $8,415,291,852.
In 2026, CTMX is forecast to generate $6,133,812,728 in revenue, with the lowest revenue forecast at $3,895,968,450 and the highest revenue forecast at $7,905,699,179.